Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy

Development of biological assays for screening thymidine analogues as potent and selective PET probes of human thymidine kinases.

Rui Huang, Li-Peng Yap, Liya Wang, Aida Kouhi, Peter Conti and Kai Chen
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 507;
Rui Huang
1Department of Radiology, University of Southern California, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li-Peng Yap
1Department of Radiology, University of Southern California, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liya Wang
2Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural Sciences, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aida Kouhi
1Department of Radiology, University of Southern California, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Conti
1Department of Radiology, University of Southern California, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kai Chen
1Department of Radiology, University of Southern California, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

507

Objectives The aim of this study was to develop a methodological platform for the screening of novel thymidine analogues that can be used as PET probes targeted to the measurement of thymidine kinase level in tumor proliferation.

Methods Human recombinant TK-1 and TK-2 were expressed in E. coli as fusion protein containing an N-terminal His-tag and a thrombin cleavage site, and purified by using metal affinity chromatography. Kinetic binding parameters of thymidine analogues (FMAU as a control) were determined by using a phosphotransferase assay with 32P-ATP as a labeled substrate. The data were fitted into the Michaelis-Menten equation. The Km, Vmax, and kcat values were calculated using subunit molecular weight of the enzymes. Inhibition assays were performed using the DE-81 filter paper with 3H-dT as a substrate. The mode of inhibition and Ki values were derived from the Dixon plots.

Results The specific activity of TK-1 and TK-2 was measured to be 2637±132 and 1872±95 nmol/min/mg, respectively. The phosphotransferase assay showed that FMAU is a substrate for both TK-1 (Km=32.5±1.2µM) and TK-2 (Km=72.3±3.7µM), whereas a new thymidine analogue (T07) is a good substrate of TK-2 (Km=44.6±5.0µM) but not TK-1. As determined by the inhibition assay, FMAU inhibited the phosphorylation of 3H-dT for both TK-1 (Ki=70±4µM) and TK-2 (Ki=4.9±0.3µM). However, T07 showed excellent potency and selectivity for TK-2. T07 was determined to be an uncompetitive inhibitor of 3H-dT for TK-1 (Ki=192.2±8µM), and a competitive inhibitor of 3H-dT for TK-2 (Ki=0.017±0.001µM).

Conclusions A reliable method for the screening of thymidine analogues has been successfully developed. The hits identified from biological assays can be used as PET probes for specifically measuring thymidine kinase level in tumor proliferation.

Research Support This work was supported by the SNMMI Mitzi & William Blahd Research Grant, the Whittier Grant for Translational Research, and the USC Department of Radiology.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 56, Issue supplement 3
May 1, 2015
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Development of biological assays for screening thymidine analogues as potent and selective PET probes of human thymidine kinases.
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Development of biological assays for screening thymidine analogues as potent and selective PET probes of human thymidine kinases.
Rui Huang, Li-Peng Yap, Liya Wang, Aida Kouhi, Peter Conti, Kai Chen
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 507;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Development of biological assays for screening thymidine analogues as potent and selective PET probes of human thymidine kinases.
Rui Huang, Li-Peng Yap, Liya Wang, Aida Kouhi, Peter Conti, Kai Chen
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 507;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy

  • Generation and validation of a surrogate truth model for xSPECT Bone concordance analysis
  • Investigation of volume-of-interest (VOI) definition methods for estimating organ activity concentrations in quantitative SPECT (QSPECT)
  • SUVmax of Normal Tissues in Pediatric and Adult Patients on FDG PET/MR
Show more Oncology: Basic, Translational & Therapy

FDG PET/CT

  • 18F-FDG uptake in non-small cell lung cancer: Warburg effect, reverse Warburg effect or Pasteur effect?
  • Novel RGD peptide derivatives with enhanced pharmacokinetics for PET imaging
  • The use of 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET) as a pathway specific biomarker with AZD8186; a PI3Kβ/δ inhibitor.
Show more FDG PET/CT

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire